KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.80

Treatment-Related Changes in Cerebrospinal Fluid Markers of Oxidative Stress and Neurodegeneration during Therapy for Childhood Acute Lymphoblastic Leukemia.

Yongkyu Park, Nirajan K C, Jeremy Willekens, Chadni Patel, Beth A Savage, Haiqun Lin, Alysta Paneque, Robert Daly, Alexandra Thrope, Melissa A Burns, Jennifer J G Welch, Justine M Kahn, Kara M Kelly, Thai-Hoa Tran, Bruno Michon, Lisa Gennarini, Lewis B Silverman, Stephen A Sands, Peter D Cole

Cancer Epidemiol Biomarkers Prev 34(11) 2015-2024

PMID40905823
PMCIDPMC12476283
DOI10.1158/1055-9965.EPI-25-1058
发表日期2025-09-04
入排依据:The study is an oncology randomized Phase III trial involving a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint. It focuses on cerebrospinal fluid biomarkers of neurotoxicity, not on survival or progression outcomes required for eligibility.
已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。
摘要

摘要

BACKGROUND: Survivors of childhood acute lymphoblastic leukemia (ALL) frequently exhibit treatment-related neurocognitive impairment, although there is substantial interpatient variability in this outcome. Analysis of biomarkers that reflect the impact of chemotherapy during the two years of treatment for ALL offers the potential to identify children who have subclinical treatment-related neurotoxicity at a time when a protective intervention could prevent the development of persistent impairment. METHODS: We prospectively measured markers indicative of oxidative stress (8-hydroxydeoxyguanosine) and neurodegeneration (total tau) in cerebrospinal fluid (CSF) collected at five timepoints before and during the first year of chemotherapy for ALL among 529 patients enrolled on Dana-Farber Cancer Institute ALL Consortium protocol 16-001 (NCT03020030). RESULTS: CSF 8-hydroxydeoxyguanosine and total tau change significantly over time, with parallel increases emerging during intensive phases of therapy, especially following repeated doses of intrathecal chemotherapy. A concordant increase in both markers was observed in 50% of patients; a concordant decrease was seen in a smaller subset (15%). In multivariable analysis, higher CSF tau was significantly associated with White race and non-Hispanic ethnicity. CONCLUSIONS: Analysis of CSF collected prospectively in a large cohort of children treated for ALL demonstrated significant changes in markers of oxidative stress and neurodegeneration within three months of treatment initiation. IMPACT: The clinical relevance of the putative biomarkers reported here will be validated by testing whether they are predictive of treatment-related cognitive decline. These biomarkers may then serve as surrogate markers for testing the efficacy of protective interventions designed to protect against treatment-induced neurotoxicity and cognitive decline.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Treatment-related changes in CSF 8OHdG among patients treated on DFCI protocols 16–001 (Panel A) and 11–001 (Panel B). At each timepoint, the number of samples analyzed is indicated. Boxplots illustrate medians and interquartile ranges, and bars indicate 10 th to 90 th percentiles. Asterisks indicate significance of post-hoc between-group comparisons: *, p <0.05; **, p <0.01; ***, p <0.001; ****, p <0.0001.
非 KM Figure
Figure 2Figure 2.. Treatment-related changes in CSF tau protein among patients treated on DFCI protocols 16–001 (Panel A) and 11–001 (Panel B). At each timepoint, the number of samples analyzed is indicated. Boxplots illustrate medians and interquartile ranges, and bars indicate 10 th to 90 th percentiles. Asterisks indicate significance of post-hoc between-group comparisons: *, p <0.05; **, p <0.01; ***, p <0.001; ****, p <0.0001.
非 KM Figure
Figure 3Figure 3.. Treatment-related changes in CSF tau protein were significantly associated with race, ethnicity, and sex, while CSF 8OHdG was not significantly associated with these demographic factors. Average CSF 8OHdG (±standard error of the mean) and tau protein are shown at each timepoint, separated by self-identified race, Hispanic ethnicity, and sex. Significant differences between groups at each timepoint are indicated by asterisks: *, p <0.05; **, p <0.01; ***, p <0.001; ****, p <0.0001.
非 KM Figure
Figure 4Figure 4.. Correlation in changes from F1 to F3 in CSF 8OHdG and tau. The difference from F1 to F3 in CSF 8OHdG and tau (measured as the value at F3 minus F1) are plotted for patients treated on protocol 16–001 with paired samples at the two timepoints (n=375). The solid blue line indicates the linear regression of the difference from F1 to F3 for the two markers. Patients with an increase over this time period in both markers (n=186; 50%) are shown in red, while those with a decrease in both markers (n=55; 15%) are shown in green.
非 KM Figure